News
Scholar Rock gets first drug approval as FDA okays Isembyld
Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.
News
Resistance grows to Recordati's private equity takeover
The offer for Recordati by private equity firms CVC and GBL undervalues the company and is unfair to minority shareholders, claims activist investor.
News
Novo Nordisk rebrands as Novo as new CEO charts turnaround
Embroiled in a fight to retain market share in weight loss and diabetes therapies, Novo Nordisk has rebranded and launched a new corporate culture.
News
Hengrui gets world-first okay for platelet drug hetrombopag
Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Sales & Marketing
Pharma's engagement problem: Are we expecting too much from ...
The question is no longer simply how to attract healthcare professionals to an event. The bigger challenge is how to create meaningful engagement.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
